Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Melanoma Clinical Trials in Pittsburgh | 249 Studies

Clinical Trials MelanomaPittsburgh

Melanoma Clinical Trials in Pittsburgh

Find 249 clinical trials for melanoma near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 41-60 of 249 trials

RecruitingTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or…NCT04851119·Birmingham, Alabama and 20 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedVaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaRATIONALE: Vaccines may make the body build an immune response to kill tumor cells.NCT00089193·Washington D.C., District of Columbia and 4 others

CompletedSafety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV MelanomaTo determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.NCT00610857·Pittsburgh, Pennsylvania

RecruitingA Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesThis phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has…NCT04511013·Birmingham, Alabama and 330 others

Active not recruitingA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryThis study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called…NCT05608291·La Jolla, California and 210 others

TerminatedPembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaThe primary objectives of the Phase 1b part of the study are to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in…NCT02263508·Birmingham, Alabama and 160 others

TerminatedA Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker StudyThis study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.NCT02796352·Pittsburgh, Pennsylvania

CompletedColony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid TumorsRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00003597·Long Beach, California and 23 others

Active not recruitingA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients…NCT02339571·Birmingham, Alabama and 762 others

TerminatedElesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells.NCT00522834·Tucson, Arizona and 100 others

CompletedA Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionThe purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or…NCT03980314·Hartford, Connecticut and 36 others

TerminatedSafety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaPatients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together…NCT04655157·Pittsburgh, Pennsylvania

TerminatedComparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryThis phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine versus stereotactic radiosurgery alone in treating patients…NCT04588246·Tucson, Arizona and 80 others

CompletedA Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic MelanomaThe purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and…NCT00304525·Aurora, Colorado and 10 others

Active not recruitingZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaThe main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.NCT05130177·Pittsburgh, Pennsylvania

Not yet recruitingNeoadjuvant RP2 + Nivolumab in Patients With MelanomaThis is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery.NCT07862530·Pittsburgh, Pennsylvania

CompletedMultiple Antigen-Engineered DC Vaccine for MelanomaThis clinical trial is to determine if the addition of a standard of care drug, interferon-alfa 2b (IFN), with an investigation vaccine will have any affect on the immune system…NCT01622933·Pittsburgh, Pennsylvania

CompletedStudy to Compare Two Formulations of CP-675,206 Monoclonal AntibodyThis is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used…NCT00431275·Scottsdale, Arizona and 7 others

CompletedDabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical…NCT01682083·Birmingham, Alabama and 167 others

TerminatedA Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsA multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.NCT05576077·Irvine, California and 12 others

PreviousPage 3 of 13Next

Other Conditions in Pittsburgh

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma